288067-35-6

Usage

Chemical Properties

white crystalline

InChI:InChI=1/C7H4BrNO/c8-6-2-1-5(4-9)7(10)3-6/h1-3,10H

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 330793-38-9 4-bromo-2-methoxybenzonitrile 
• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 
• 591-20-8 3-Bromophenol 

Downstream Products

• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 1261494-95-4 4-bromo-2-(difluoromethoxy)benzonitrile 
• 693232-03-0 2-(benzyloxy)-4-bromobenzonitrile 
• 945724-02-7 (E)-1-(4-bromo-2-hydroxyphenyl)-3-(dimethylamino)prop-2-en-1-one 
• 168759-60-2 7-bromo-4H-benzopyran-4-one 
• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 

Relevant academic research and scientific papers

Lewis acid-promoted site-selective cyanation of phenols

An efficient Lewis acid-promoted site-selective electrophilic cyanation of 3-substituted and 3,4-disubstituted phenols has been developed. The cyanation reactions using MeSCN as the cyanating reagent proceeded efficiently to afford a wide range of 2-hydroxybenzonitriles with high efficiency and excellent regioselectivity. This protocol could provide a practical method for the synthesis and modification of biologically active molecules.

Pyrrolopyrimidine vs Imidazole-Phenyl-Thiazole Scaffolds in Nonpeptidic Dimerization Inhibitors of Leishmania infantum Trypanothione Reductase

Disruption of protein-protein interactions of essential oligomeric enzymes by small molecules represents a significant challenge. We recently reported some linear and cyclic peptides derived from an α-helical region present in the homodimeric interface of Leishmania infantum trypanothione reductase (Li-TryR) that showed potent effects on both dimerization and redox activity of this essential enzyme. Here, we describe our first steps toward the design of nonpeptidic small-molecule Li-TryR dimerization disruptors using a proteomimetic approach. The pyrrolopyrimidine and the 5-6-5 imidazole-phenyl-thiazole α-helix-mimetic scaffolds were suitably decorated with substituents that could mimic three key residues (K, Q, and I) of the linear peptide prototype (PKIIQSVGIS-Nle-K-Nle). Extensive optimization of previously described synthetic methodologies was required. A library of 15 compounds bearing different hydrophobic alkyl and aromatic substituents was synthesized. The imidazole-phenyl-thiazole-based analogues outperformed the pyrrolopyrimidine-based derivatives in both inhibiting the enzyme and killing extracellular and intracellular parasites in cell culture. The most active imidazole-phenyl-thiazole compounds 3e and 3f inhibit Li-TryR and prevent growth of the parasites at low micromolar concentrations similar to those required by the peptide prototype. The intrinsic fluorescence of these compounds inside the parasites visually demonstrates their good permeability in comparison with previous peptide-based Li-TryR dimerization disruptors.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

no abstract published

Synthesis of benzyloxycyanophenylboronic esters

The synthesis of six new benzyloxycyanoboronic esters: 2-benzyloxy-6- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (4a), 4-benzyloxy-2- cyanophenyl-4,4,5, 5-tetramethyl-[1,3,2]dioxaborolane (4b), 4-benzyloxy-3- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (8a), 2-benzyloxy-5- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (8b), 3-benzyloxy-4- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12a), and 2-benzyloxy-5-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12b) is reported. Copyright by Walter de Gruyter Berlin Boston.

BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to benzofuran and benzothiophene derivatives and compositions containing such compounds for the production of medicaments for the treatment of cancers of the central nervous system as monotherapy or combination with other agents.

CARBAMOYL-TYPE BENZOFURAN DERIVATIVES

The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R4 and R5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R3 is a hydrogen atom, etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.

BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS

The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

Synthesis of Benzyloxybromobenzonitriles

The synthesis of four new benzyloxybromobenzonitriles including: 2-benzyloxy-4-bromobenzonitrile (3), 3-benzyloxy-4-bromobenzonitrile (7), 5-benzyloxy-2-bromobenzonitrile (11) and 3-benzyloxy-2-bromobenzonitrile (12) is reported.

Calcilytic compounds

Novel calcilytic compounds and methods of using them are provided.

BENZOFURAN DERIVATIVE

The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: -N="or" -CH=; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.